CODEXIS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • February 27th, 2023 • Codexis, Inc. • Industrial organic chemicals • Delaware
This Indemnification Agreement (“Agreement”) is effective as of December 16, 2022, by and between Codexis, Inc., a Delaware corporation (the “Company”), and [INDEMNITEE] (“Indemnitee”).
CHANGE OF CONTROL SEVERANCE AGREEMENTChange of Control Severance Agreement • February 27th, 2023 • Codexis, Inc. • Industrial organic chemicals • California
This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between Sri Ryali (the “Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
AMENDMENT NO. 1 TO ENZYME SUPPLY AGREEMENTEnzyme Supply Agreement • February 27th, 2023 • Codexis, Inc. • Industrial organic chemicals
This Amendment No. 1 to Enzyme Supply Agreement (this “Amendment No. 1”) is made as of December 19, 2022 (the “Amendment No. 1 Effective Date”), between Codexis, Inc., a Delaware corporation having its principal offices at 200 Penobscot Drive, Redwood City, California 94063 (“Codexis”) and Pfizer Ireland Pharmaceuticals, an Irish corporation, with its principal place of business at Operations Support Group, Ringaskiddy, Cork, Ireland, and its Affiliates (“Pfizer”). Codexis and Pfizer may each be referred to herein individually as a “Party” or collectively, as the “Parties.”
ENZYME SUPPLY AGREEMENTEnzyme Supply Agreement • February 27th, 2023 • Codexis, Inc. • Industrial organic chemicals • New York
THIS ENZYME SUPPLY AGREEMENT, including the exhibits attached hereto (the “Agreement”), effective as of October 30, 2021 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America (“Codexis”), and Pfizer Ireland Pharmaceuticals, an Irish corporation, with its principal place of business at Operations Support Group, Ringaskiddy, Cork, Ireland, and its Affiliates (“Pfizer”). Codexis and Pfizer each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
AMENDMENT NO. 2 TO ENZYME SUPPLY AGREEMENTEnzyme Supply Agreement • February 27th, 2023 • Codexis, Inc. • Industrial organic chemicals
This Amendment No. 2 to Enzyme Supply Agreement (this “Amendment”) is made as of February 1, 2023 (the “Amendment Effective Date”), between Codexis, Inc., a Delaware corporation having its principal offices at 200 Penobscot Drive, Redwood City, California 94063 (“Codexis”) and Pfizer Ireland Pharmaceuticals, an Ireland corporation, with its principal place of business at Operations Support Group, Ringaskiddy, Cork, Ireland, and its Affiliates (“Pfizer”). Codexis and Pfizer may each be referred to herein individually as a “Party” or collectively, as the “Parties.”
TRANSITION AND SEPARATION AGREEMENTTransition and Separation Agreement • February 27th, 2023 • Codexis, Inc. • Industrial organic chemicals • California
This Transition and Separation Agreement (the “Agreement”) by and between Ross Taylor (“Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts:
